• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.260 -0.040 (-3.08%)
Official Closing Price Updated: 6:30 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
January 29, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Partners with CRO to Advance NV-387 Antiviral Drug to Phase II Trials
January 27, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Engages CRO for Phase II Clinical Trial
January 27, 2025
Via ACCESS Newswire
News headline image
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present Broad-Spectrum Antiviral Innovations at Biotech Showcase 2025
January 13, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals
January 08, 2025
Via ACCESSWIRE
News headline image
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
October 08, 2024
Via ACCESSWIRE
News headline image
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
January 13, 2025
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387 as a Broad-Spectrum Antiviral Solution to Emerging Threats
January 08, 2025
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Touts NV-387 as Key Defense Against Potential Bird Flu Pandemic
December 23, 2024
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
December 23, 2024
Via ACCESSWIRE
News headline image
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
November 27, 2024
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Financial Progress and Advances Towards Key Phase II Clinical Trials
November 15, 2024
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
November 15, 2024
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Advancements at Spartan Capital Investors Conference
November 04, 2024
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
November 03, 2024
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform and Drug Delivery Advances at PODD Conference
October 22, 2024
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides President Dr. Diwan to Present at the PODD Conference
October 22, 2024
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) CEO Featured in Latest Episode of PODD Podcast
October 15, 2024
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
October 15, 2024
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) to Discuss Its ‘Trojan Horse’ Platform Technology at Upcoming Global AMR Summit
October 08, 2024
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Announces Filing of Fiscal 2024 Form 10-K
September 30, 2024
Via Investor Brand Network
News headline image
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
September 30, 2024
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Announces Execution of MoU Agreement with TheraCour Pharma
September 26, 2024
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
September 26, 2024
Via ACCESSWIRE
News headline image
MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
August 26, 2024
Via ACCESSWIRE
News headline image
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -
A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
August 19, 2024
Via ACCESSWIRE
News headline image
NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
August 08, 2024
Via ACCESSWIRE
News headline image
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
August 06, 2024
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?
August 02, 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 2, 2024) - Investorideas.com, a go-to investing platform covering biotech and... 
Via Newsfile
News headline image
"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides
August 01, 2024
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap